Phase III KEYNOTE-355 study of pembrolizumab (pembro) vs placebo (pbo) plus chemotherapy (chemo) for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC): Results for patients (Pts) enrolled in Asia

被引：3
|
作者：
Yusof, M. Md [1 ]
Cescon, D. W. [2 ]
Rugo, H. S. [3 ]
Im, S-A. [4 ]
Gallardo, C. [5 ]
Lipatov, O. [6 ]
Barrios, C. H. [7 ]
Holgado, E. [8 ,9 ,10 ]
Iwata, H. [11 ]
Masuda, N. [12 ]
Gokmen, E. [13 ]
Loi, S. [14 ]
Guo, Z. [15 ]
Jensen, E. [15 ]
Aktan, G. [16 ]
Karantza, V. [16 ]
Schmid, P. [17 ]
Cortes, J. [18 ,19 ,20 ,21 ]
机构：
[1] Pantai Hosp, Dept Oncol, Kuala Lumpur, Malaysia
[2] Univ Toronto, Princess Margaret Canc Ctr, Toronto, ON, Canada
[3] Univ Calif San Francisco, Dept Hematol Oncol, Ctr Comprehens Canc, San Francisco, CA 94143 USA
[4] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea
[5] Arturo Lopez Perez Fdn, Inst Oncol, Santiago, Chile
[6] Republican Clin Oncol Dispensary, Dept Oncol, Republic Bashkortostan, Russia
[7] Pontificia Univ Catolica Rio Grande do Sul, HSL, Ctr Pesquisa Oncol, Dept Med, Porto Alegre, RS, Brazil
[8] IOB Inst Oncol, Quironsalud Grp, Breast Canc Program, Madrid, Spain
[9] IOB Inst Oncol, Quironsalud Grp, Breast Canc Program, Barcelona, Spain
[10] Ramon & Cajal Univ Hosp, Madrid, Spain
[11] Aichi Canc Ctr Hosp, Dept Breast Oncol, Nagoya, Aichi, Japan
[12] Osaka Natl Hosp, Natl Hosp Org, Dept Surg, Breast Oncol, Osaka, Japan
[13] Ege Univ, Dept Med Oncol, Med Fac, Izmir, Turkey
[14] Peter MacCallum Canc Inst, Dept Res & Canc Med, Melbourne, Vic, Australia
[15] Merck & Co Inc, Biostat, Kenilworth, NJ USA
[16] Merck & Co Inc, Oncol, Kenilworth, NJ USA
[17] Barts Canc Inst, Centre Expt Canc Med, London, England
[18] IOB Inst Oncol, Breast Canc Program, Quironsalud Grp, Madrid, Spain
[19] IOB Inst Oncol, Breast Canc Program, Quironsalud Grp, Barcelona, Spain
[20] Vall dHebron Inst Oncol, Madrid, Spain
[21] Vall dHebron Inst Oncol, Barcelona, Spain
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.10.063
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
430
引用
收藏
页码：S1257 / S1257
页数：1
相关论文
共 50 条
  • [31] Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A.
    Adams, Sylvia
    Schmid, Peter
    Rugo, Hope S.
    Winer, Eric P.
    Loirat, Delphine
    Awada, Ahmad
    Cescon, David W.
    Iwata, Hiroji
    Campone, Mario
    Nanda, Rita
    Hui, Rina
    Curigliano, Giuseppe
    Toppmeyer, Deborah
    O'Shaughnessy, Joyce
    Loi, Sherene
    Paluch-Shimon, Shani
    Card, Deborah
    Zhao, Jing
    Karantza, Vassiliki
    Cortes, Javier
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [32] KEYNOTE-173: Phase 1b multicohort study of pembrolizumab (Pembro) in combination with chemotherapy as neoadjuvant treatment for triple-negative breast cancer (TNBC)
    Schmid, P.
    Park, Y. H.
    Munoz-Couselo, E.
    Kim, S-B
    Sohn, J.
    Im, S-A
    Holgado, E.
    Foukakis, T.
    Kuemmel, S.
    Dent, R.
    Yin, L.
    Ding, Y.
    Tryfonidis, K.
    Cortes, J.
    CANCER RESEARCH, 2019, 79 (04)
  • [33] KEYNOTE-585: Phase 3 study of chemotherapy (chemo) plus pembrolizumab (pembro) vs chemo plus placebo as neoadjuvant/adjuvant treatment for patients (pts) with gastric or gastroesophageal junction (G/GEJ) cancer.
    Bang, Yung-Jue
    Van Cutsem, Eric
    Fuchs, Charles S.
    Ohtsu, Atsushi
    Tabernero, Josep
    Ilson, David H.
    Hyung, Woo Jin
    Strong, Vivian E.
    Goetze, Thorsten Oliver
    Yoshikawa, Takaki
    Tang, Laura H.
    Hwang, Peggy May Tan
    Shitara, Kohei
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [34] Relationship between tumor infiltrating lymphocytes (TILs) and response to pembrolizumab (Pembro) plus chemotherapy (Chemo) as neoadjuvant treatment (NAT) for triple-negative breast cancer (TNBC): phase Ib KEYNOTE-173 trial
    Loi, S.
    Schmid, P.
    Cortes, J.
    ark, Y. H.
    Munoz-Couselo, E.
    Kim, S-B
    Sohn, J.
    Im, S-A
    Holgado, E.
    Foukakis, T.
    Kuemmel, S.
    Dent, R.
    Wang, A.
    Aktan, G.
    Karantza, V.
    Salgado, R.
    CANCER RESEARCH, 2019, 79 (04)
  • [35] Sacituzumab tirumotecan (SKB264/MK-2870) in patients (pts) with previously treated locally recurrent or metastatic triple-negative breast cancer (TNBC): Results from the phase III OptiTROP-Breast01 study
    Xu, Binghe
    Yin, Yongmei
    Fan, Ying
    Ouyang, Quchang
    Song, Lihua
    Wang, Xiaojia
    Li, Wei
    Li, Man
    Yan, Xi
    Wang, Shusen
    Sun, Tao
    Teng, Yuee
    Tang, Xianjun
    Tong, Zhongsheng
    Sun, Zhengkui
    Jin, Xiaoping
    Diao, Yina
    Liu, Gesha
    Ge, Junyou
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [36] Phase I/I study of niraparib plus pembrolizumab in patients with triple-negative breast cancer or recurrent ovarian cancer (KEYNOTE-162).
    Konstantinopoulos, Panagiotis
    Moore, Kathleen N.
    Sachdev, Jasgit C.
    Mita, Monica M.
    Vinayak, Shaveta
    Seward, Shelly Marie
    Karantza, Vassiliki
    Aktan, Gursel
    Ferguson, Andrew
    Bobilev, Dmitri
    Matulonis, Ursula A.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [37] A phase II multicenter, randomized, placebo controlled, double-blind study of CC-486 plus pembrolizumab (pembro) vs pembro plus placebo (PBO) in previously treated patients (pts) with locally advanced/metastatic non-small cell lung cancer (NSCLC).
    Levy, Benjamin Philip
    Giaccone, Giuseppe
    Besse, Benjamin
    Begic, Damir
    Wu, Xiaoling
    Fandi, Abderrahim
    Paz-Ares, Luis
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [38] Phase III study of perioperative pembrolizumab (pembro) plus neoadjuvant chemotherapy (chemo) versus placebo plus neoadjuvant chemo in cisplatin-eligible patients (pts) with muscle-invasive bladder cancer (MIBC): KEYNOTE-866
    Siefker-Radtke, Arlene O.
    Steinberg, Gary D.
    Bedke, Jens
    Nishiyama, Hiroyuki
    Fang, Xiao
    Kataria, Ritesh
    Moreno, Blanca Homet
    Hoimes, Christopher J.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [39] Association of tumor mutational burden (TMB) and clinical outcomes with pembrolizumab (pembro) versus chemotherapy (chemo) in patients with metastatic triple-negative breast cancer (mTNBC) from KEYNOTE-119.
    Winer, Eric P.
    Lipatov, Oleg
    Im, Seock-Ah
    Goncalves, Anthony
    Munoz-Couselo, Eva
    Lee, Keun Seok
    Schmid, Peter
    Testa, Laura
    Witzel, Isabell
    Ohtani, Shoichiro
    Lunceford, Jared
    Karantza, Vassiliki
    Mejia, Jaime Alberto
    Cristescu, Razvan
    Aurora-Garg, Deepti
    Jelinic, Petar
    Huang, Lingkang
    Cortes, Javier
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [40] Results of KEYNOTE-122: A phase III study of pembrolizumab (pembro) monotherapy vs chemotherapy (chemo) for platinum-pretreated, recurrent or metastatic (R/M) nasopharyngeal carcinoma (NPC)
    Chan, A. T.
    Lee, V. H. F.
    Hong, R-L.
    Ahn, M-J.
    Chong, W. Q.
    Kim, S-B.
    Fuang, H. Gwo
    Caguioa, P. B.
    Ngamphaiboon, N.
    Ho, C.
    Aziz, M. A. S. Abdul
    Ng, Q. S.
    Yen, C-J.
    Soparattanapaisarn, N.
    Ngan, K. C. R.
    Kho, S. K.
    Swaby, R.
    Saraf, S.
    Ge, J.
    Siu, L. L.
    ANNALS OF ONCOLOGY, 2021, 32 : S786 - S786
12345